biostudies-literatureUnknown12Saleh KM<h4>Background</h4>Pulmonary arterial hypertension (PAH) is a progressive, fatal cardiopulmonary disorder characterized by elevated pulmonary vascular resistance leading to right heart failure. Current treatment utilizes pathway-specific vasodilators, including numerous prostacyclin therapies with diverse delivery methods. Despite available options, head-to-head studies comparing these treatments remain scarce.<h4>Aim</h4>This network meta-analysis seeks to systematically evaluate all prostacyclin-based PAH therapies to guide clinical decision-making regarding treatment selection.<h4>Methods</h4>We implemented a frequentist approach to network meta-analysis (NWM). For continuous outcomes, we calculated pooled mean differences (MD), whereas risk ratios (RR) were determined for binary endpoiFrontiers in medicine1643220https://www.ebi.ac.uk/biostudies/studies/S-EPMC12554579biostudies-literatureComparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis.PMC12554579Alazazzi HBodi GMallat JMohammed SIqbal TSabbour HElhennawi MSaleh KMSalim SfalseComparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis.<h4>Background</h4>Pulmonary arterial hypertension (PAH) is a progressive, fatal cardiopulmonary disorder characterized by elevated pulmonary vascular resistance leading to right heart failure. Current treatment utilizes pathway-specific vasodilators, including numerous prostacyclin therapies with diverse delivery methods. Despite available options, head-to-head studies comparing these treatments remain scarce.<h4>Aim</h4>This network meta-analysis seeks to systematically evaluate all prostacyclin-based PAH therapies to guide clinical decision-making regarding treatment selection.<h4>Methods</h4>We implemented a frequentist approach to network meta-analysis (NWM). For continuous outcomes, we calculated pooled mean differences (MD), whereas risk ratios (RR) were determined for binary endpoi2025-01-01T00:00:00Z20252026-06-05T07:53:20.688Z2026-05-14T03:12:55.233ZS-EPMC125545794115846510.3389/fmed.2025.1643220